Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
DESCRIPTION: (Adapted from the Investigator's abstract): Rheumatoid factors
autologous IgG present in the synovial fluid of patients with rheumatoid
arthritis. High levels of RF-containing immune complexes and/or cryoglobulins
have also been found in patients with microbial infections such as infectious
endocarditis, in individuals presenting with hepatitis C-related essential
mixed cryogloblulinemia, and in Fas/FasL-deficient (lpr/gld) mice. These immune
complexes can deposit in blood vessel walls, fix complement, and thereby
promote the vasculitis and glomerulonephritis associated with these diseases.
Thus the contribution of RF to the effector arm of systemic autoimmune disease
is well documented. Nevertheless, exactly how RF+ B cells become activated, why
RF so frequently present as monoclonal gammopathies, and what role RF+ B cells
might play in the initiation and propagation of the autoimmune cascade are
questions that remain unresolved. The intent of the current application is to
address these questions by using an RF+ B cell receptor transgenic mouse line,
developed from a prototypic MRL/lpr-derived autoantibody, to evaluate the role
RF+ B cells might play in the presentation of autoantigens. Specifically, the
project will be organized to:
(1) determine the ability of monomeric IgG2a and different types of
IgG2a-containing immune complexes to activate RF+ B cells and evaluate the
ability of activated and non-activated RF+ B cells to process and present
autoantigenic epitopes; (2) evaluate the ability of RF+ B cells to stimulate
autoreactive T cells in vitro and determine the specificity of the RF-activated
ART; and (3) assess the ability of RF+ B cells and/or RF -activated ART to
trigger and propagate systemic autoimmune disease. While dealing with RF in
particular, the results of these experiments should be applicable to a more
general understanding of the principles governing self/nonself recognition and
tolerance induction. Moreover, this experimental strategy should also have
direct relevance to human clinical syndromes associated with excessive RF
production.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
846
DUNS Number
604483045
UEI
FBYMGMHW4X95
Project Start Date
22-September-1986
Project End Date
09-August-2006
Budget Start Date
01-March-2005
Budget End Date
09-August-2006
Project Funding Information for 2005
Total Funding
$309,700
Direct Costs
$190,000
Indirect Costs
$119,700
Year
Funding IC
FY Total Cost by IC
2005
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$309,700
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AR035230-18
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AR035230-18
Patents
No Patents information available for 5R01AR035230-18
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AR035230-18
Clinical Studies
No Clinical Studies information available for 5R01AR035230-18
News and More
Related News Releases
No news release information available for 5R01AR035230-18
History
No Historical information available for 5R01AR035230-18
Similar Projects
No Similar Projects information available for 5R01AR035230-18